Glycoengineered obinutuzumab activates purified PMNs more efficiently than wild-type rituximab. CLL (panels A-C) or BJAB targets (panel D) were opsonized with 1 to 100 µg/mL of nonglycoengineered wild-type rituximab (WT-RTX), glycoengineered obinutuzumab (GE-OBZ), or control TRZ antibodies and incubated with purified PMNs from healthy donors at a 1:3 E:T ratio. PMA was used as a control. CD11b (panel A), CD62L (panel B), or ROS expression (panels C-D) on PMNs was analyzed by flow cytometry after 24 hours, 6 hours, or 1 hour, respectively. The data are the means and standard deviations of 2 to 4 experiments.